Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
MétaboliqueMédicament approuvé

Lemon Bottle

Recherche publiée et base de preuves

Injectable lipolysis has been studied mainly as deoxycholic acid (ATX-101), a synthetic bile salt approved for submental fat reduction on the basis of two phase 3 randomised trials (REFINE-1 and REFINE-2), and as compounded phosphatidylcholine/sodium deoxycholate formulations, which were never approved for this use. Preclinical work indicated that the deoxycholate component, acting as a detergent that disrupts cell membranes, was the principal adipocytolytic agent rather than phosphatidylcholine. The reported adverse-event profile includes injection-site swelling and induration, marginal mandibular nerve paresis, skin ulceration and necrosis, fibrosis, and post-procedural infection, with animal data documenting demyelinating nerve injury after intrafascicular exposure. The branded product marketed as 'Lemon Bottle' was not identified in any peer-reviewed clinical or mechanistic study, so the evidence described here relates to deoxycholic acid and phosphatidylcholine/deoxycholate rather than to that specific formulation.

En bref
  • Lemon Bottle est un produit injectable ; aucune étude évaluée n'a été trouvée.
  • Des études sur l'acide désoxycholique ont rapporté une réduction de graisse.
  • Aucune recherche publiée ne caractérise spécifiquement la formulation Lemon Bottle.

39 études · 15 depuis 2023 · plus récente 2026

Études citées
39
Publiées 2023+
15
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • Deoxycholic acid (ATX-101) as an approved injectable for submental fat, supported by two phase 3 randomised placebo-controlled trials
  • Sodium deoxycholate as a non-selective detergent causing adipocyte membrane lysis
  • Marginal mandibular nerve paresis, dysphagia, skin ulceration and necrosis as recurring serious adverse events
  • Compounded phosphatidylcholine/deoxycholate lipolysis and its association with fibrosis, granuloma, heterotopic ossification and atypical infection
  • Non-submental and off-label body applications supported mostly by small, non-randomised studies
  • Absence of the 'Lemon Bottle' branded lipolytic from the indexed peer-reviewed literature

Les preuves

39 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2025

    A Systematic Review of Injectable Lipolytic agents for Non-Submental Fat Reduction

    Carrion K, Salingaros S, Bernal C, Barger BT, Lipman KJ, et al. · Plastic and Reconstructive Surgery · systematic review of 25 studies, 3178 patients, deoxycholic acid and phosphatidylcholine at non-submental sites

    Reductions in localised adiposity were reported in 93.75% of the included studies, with adverse events described as generally mild and transient and satisfaction ranging from 57.1% to 86%. The authors noted heterogeneous protocols and called for further controlled trials to standardise treatment.

  2. 02Revue systématique2024

    Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations

    Shridharani SM, Kennedy ML · Aesthetic Surgery Journal Open Forum · systematic review of reported serious adverse events after deoxycholic acid injection

    The review catalogued serious adverse events reported after ATX-101 treatment of the submental region and jowls and set out management approaches for each. Contributing factors identified included intradermal rather than subcutaneous placement and inadequate assessment of fat pad thickness.

  3. 03Revue systématique2023

    Efficacy, safety, and potential industry bias in using deoxycholic acid for submental fat reduction ‒ A systematic review and meta-analysis of randomized clinical trials.

    Inocêncio GSG, et al. · Clinics (Sao Paulo) · systematic review and meta-analysis of 5 RCTs

    Deoxycholic acid outperformed placebo on all submental fat efficacy outcomes but carried higher risks of fibrosis, pain, erythema, numbness, swelling, oedema, pruritus, nodules, headache and paresthesia. Only two trials had low risk of bias, all trials showed potential industry-sponsorship bias, and certainty of evidence was low to moderate.

    Résultat de sécurité signalé. Fibrosis, nodules and paresthesia were more frequent with deoxycholic acid than placebo across pooled RCTs.

  4. 04Clinique humaine2026

    Injection lipolysis-induced abdominal fibrosis mimicking desmoid fibromatosis

    Gkogkolou P, Arns B, Ziaja ZF, Drusenheimer J, Jasker P · Journal der Deutschen Dermatologischen Gesellschaft · single case report with histopathology after abdominal injection lipolysis

    Abdominal fibrosis developing after injection lipolysis was reported to clinically and radiologically resemble desmoid fibromatosis. Histopathological examination was required to establish the reactive nature of the lesion.

  5. 05Clinique humaine2026

    Heterotopic ossification of the masseter muscle following injection lipolysis: A case report and review

    Gaessler J, Partenheimer P, Gronewold M, Sabau R, Lentge F, et al. · Journal of Cranio-Maxillo-Facial Surgery · single case report, 35-year-old woman after jawline injection lipolysis

    Severe trismus and pain developed after jawline injection lipolysis, with imaging showing a solid mass in the right masseter muscle and histopathology confirming heterotopic ossification. Surgical excision was required.

  6. 06Clinique humaine2026

    Nocardia farcinica infection after facial lipolysis injection in an immunocompetent patient

    Xu W, Su F, Ji Y, Chen M, Hong X, Zhuo B, Ge Y · Journal of Infection in Developing Countries · single case report, immunocompetent adult after facial lipolytic injection

    Nocardia farcinica infection was documented following a facial lipolysis injection in a patient without immunodeficiency. The infection resolved with amoxicillin-clavulanate therapy.

  7. 07Clinique humaine2025

    A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults.

    Ting W, et al. · Aesthet Surg J · phase 3 randomised double-blind placebo-controlled multicentre trial, n=325 Chinese adults with moderate-to-severe submental fat, MEI005 (a deoxycholic acid-based injectable)

    At 12 weeks after treatment, 68.9% of MEI005 recipients versus 21.6% of placebo recipients improved by at least one grade on both clinician and patient scales, and 18.9% versus 1.8% by two grades (P < .001). MRI showed at least 10% submental fat volume reduction in 50% versus 15.2%; adverse events were mostly mild to moderate.

  8. 08Clinique humaine2024

    Deoxycholic Acid for Submental Convexity: A MAUDE Database Analysis

    Gibson AC, Kompelli A, Saadi C, Patel VA, Saadi RA, Shokri T · Craniomaxillofacial Trauma & Reconstruction · retrospective analysis of FDA MAUDE adverse-event reports for deoxycholic acid injection

    Among the adverse event reports analysed, excessive swelling accounted for 24%, marginal mandibular nerve weakness 19% and skin necrosis 14%. Two patients required hospitalisation for management of necrosis, both with underlying systemic disease.

  9. 09Clinique humaine2023

    Injection Adipocytolysis for Body and Jawline Contouring: Real-World Experience and Treatment Considerations.

    Shridharani SM, et al. · Aesthet Surg J · single-centre single-arm observational study, n=201 patients given ATX-101 off-label at body and jawline sites (jowl, abdomen, thigh, arm, periaxillary fat, back, knee, chest, neck)

    All patients had oedema after each session, and numbness, tenderness, bruising and paresis occurred in 99.6%, 94.2%, 33.1% and 2.6% respectively. Adverse events were localised to injection sites and alopecia was not observed.

    Résultat de sécurité signalé. Paresis was recorded in 2.6% of patients treated at body and jawline sites.

  10. 10Clinique humaine2021

    Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials

    Humphrey S, Cohen JL, Bhatia AC, Green LJ, Green JB, Bowen B · Aesthetic Surgery Journal · long-term follow-up of REFINE-1/REFINE-2 responders, 224 enrolled (113 ATX-101, 111 placebo), up to 3 years

    Maintenance of response at year 3 was reported in 82.4% of the ATX-101 group versus 65.0% of the placebo group. No new treatment-related adverse events were reported over the follow-up period.

  11. 11Clinique humaine2021

    Randomized, Placebo-Controlled Phase 1/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental Fat.

    Goodman GJ, et al. · Dermatol Surg · phase 1/2 randomised placebo-controlled multicentre trial comparing three ATX-101 concentrations with placebo, n=85 adults with submental fat, 16 weeks

    At week 16, 71%, 74% and 53% of the three ATX-101 groups versus 40% of placebo had at least a 1-grade reduction in submental fat; the change in rating score was significant versus placebo only for the two lower concentrations. Most participants had adverse events, mostly mild or moderate and apparently dose-related, with the highest pain scores at the two higher concentrations and no discontinuations.

  12. 12Clinique humaine2020

    Histological Analysis of the Effect of ATX-101 (Deoxycholic Acid Injection) on Subcutaneous Fat: Results From a Phase 1 Open-Label Study.

    Walker PS, et al. · Dermatol Surg · phase 1 open-label histology study, n=14, abdominoplasty tissue at days 1-28

    Injected abdominal fat showed changes confined to the subcutaneous layer: adipocytolysis, vessel injury and neutrophilic inflammation at day 1, lipid-laden macrophages by day 7, and septal thickening, neovascularisation and fat lobule atrophy with resolved inflammation by day 28.

  13. 13Clinique humaine2019

    A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental Fat.

    Glogau RG, et al. · Dermatol Surg · phase 3b randomised double-blind placebo-controlled trial, adults with mild or extreme submental fat (groups outside the approved moderate-severe range), ATX-101

    Composite clinician- and patient-rated response was 61.3% with ATX-101 versus 6.7% with placebo in mild submental fat and 89.3% versus 13.3% in extreme submental fat (p < .001). Skin laxity was unchanged or improved in most participants, and adverse events were mainly mild to moderate, transient and at the injection site.

  14. 14Clinique humaine2019

    ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Results From a 12-Month Open-Label Study.

    Beer K, et al. · J Drugs Dermatol · phase 3 open-label study, n=165 adults with moderate-to-extreme submental fat, ATX-101, follow-up to 12 months after the last treatment

    Twelve weeks after the last treatment, 86.8% (clinician) and 83.8% (patient) had at least a 1-grade improvement, and at 12 months 90.4% and 80.7% of these responders maintained it. Adverse events were mild to moderate and mainly in the treatment area; in the week after the first treatment 13.3% missed work and 33.9% missed social or leisure activities.

  15. 15Clinique humaine2016

    REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction

    Jones DH, Carruthers J, Joseph JH, Callender VD, Walker P, et al. · Dermatologic Surgery · phase 3 randomised double-blind placebo-controlled trial, 256 ATX-101 versus 250 placebo adults with submental fat

    A one-grade or greater improvement in submental fat rating was recorded in 70.0% of ATX-101 recipients versus 18.6% of placebo recipients. Marginal mandibular nerve paresis was reported in 4.3% of treated subjects and was described as mostly mild, transient and resolving without sequelae.

  16. 16Clinique humaine2016

    ATX-101 for reduction of submental fat: A phase III randomized controlled trial

    Humphrey S, Sykes J, Kantor J, Bertucci V, Walker P, et al. · Journal of the American Academy of Dermatology · REFINE-2 phase 3 randomised placebo-controlled trial, approximately 258 participants per arm

    A one-grade or greater composite improvement was recorded in 66.5% of ATX-101 recipients versus 22.2% of placebo recipients. Of reported adverse events, 85.7% were localised to injection sites and were characterised as mild or moderate.

  17. 17Clinique humaine2015

    A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring.

    Walker P, et al. · J Drugs Dermatol · phase 1 randomised safety and pharmacokinetic study, n=24 adults, maximal therapeutic dose of ATX-101 injected into submental fat, 24-hour monitoring including Holter ECG

    Plasma deoxycholic acid peaked rapidly and returned to the range of endogenous values by 24 hours. All participants had at least one adverse event, mostly transient, local and mild or moderate, with no deaths, serious adverse events or discontinuations and no clinically significant changes in laboratory tests, vital signs or Holter electrocardiograms.

  18. 18Clinique humaine2014

    Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study

    Ascher B, Hoffmann K, Walker P, Lippert S, Wollina U, Havlickova B · Journal of the European Academy of Dermatology and Venereology · phase 3 randomised placebo-controlled trial, 360 adults with submental fat, two ATX-101 dose levels

    Both ATX-101 dose groups showed greater clinician-rated improvement in submental fat than placebo (58.3-62.3% versus 34.5%). Patient-reported satisfaction measures also improved, and reported adverse events were predominantly mild to moderate and localised to the injection area.

  19. 19Clinique humaine2014

    Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study.

    Rzany B, et al. · Br J Dermatol · phase 3 randomised double-blind placebo-controlled multicentre trial in Europe, n=363 adults with moderate or severe submental fat, ATX-101 (deoxycholic acid) at two dose levels, 12-week follow-up

    Clinician-rated responder rates were about 59% and 65% with the two ATX-101 doses versus 23% with placebo, and more ATX-101 recipients were satisfied with their face and chin appearance (both P < 0·001). Calliper-measured submental fat decreased, skin laxity did not worsen, and most adverse events were transient and confined to the treatment area.

  20. 20Clinique humaine2013

    Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial.

    Reeds DN, et al. · Aesthet Surg J · randomised open-label within-patient controlled trial, n=13 women (seven completed), phosphatidylcholine-deoxycholate injections to one side of the lower abdomen with the other side untreated, adipose biopsies

    Anterior subcutaneous abdominal fat thickness fell significantly on the treated side (P = .004). Biopsies showed rapid increases in crown-like structures and macrophage infiltration consistent with adipocyte necrosis, while plasma C-reactive protein, lipids and glucose were unchanged.

  21. 21Clinique humaine2011

    Phosphatidylcholine for the treatment of prominent lower eyelid fat pads: a pilot study.

    Tawfik HA, et al. · Ophthalmic Plast Reconstr Surg · pilot randomised double-blind placebo-controlled within-patient trial, n=45 adults with prominent lower eyelid fat pads (23 completed), Lipostabil (phosphatidylcholine) in one lower eyelid and saline in the other

    Masked observers could not distinguish Lipostabil-injected from saline-injected eyelids, or pre- from post-treatment photographs, in most of the 23 patients who completed the study. No improvement in appearance or reduction of fullness was observed.

  22. 22Clinique humaine2009

    Randomized double-blind clinical trial of subcutaneously injected deoxycholate versus a phosphatidylcholine-deoxycholate combination for the reduction of submental fat

    Rotunda AM, Weiss SR, Rivkin LS · Dermatologic Surgery · randomised double-blind trial, 32 evaluable adults with submental fat, deoxycholate alone versus phosphatidylcholine-deoxycholate

    Both formulations produced only minimal aesthetic change, with a median improvement score of 0.5 on the scale used. No significant difference in efficacy or adverse events was detected between deoxycholate alone and the phosphatidylcholine-deoxycholate combination.

  23. 23Clinique humaine2008

    Phosphatidylcholine and sodium deoxycholate in the treatment of localized fat: a double-blind, randomized study.

    Salti G, et al. · Dermatol Surg · double-blind randomised split-body trial, thirty-seven women with localised fat (gynoid lipodystrophy), phosphatidylcholine/sodium deoxycholate on one side versus sodium deoxycholate alone on the other

    Local fat decreased in 91.9% of patients with no significant difference between sides (6.46% versus 6.77% by circumference, 36.87% versus 36.06% by ultrasound). Side effects were local and few but more pronounced on the deoxycholate-only side; no laboratory tests were done.

  24. 24Clinique humaine2008

    Injection lipolysis for reduction of saddlebag trochanteric bulges--half-side controlled pilot study.

    Kopera D, et al. · J Dtsch Dermatol Ges · half-side controlled pilot study, phosphatidylcholine + deoxycholate + ethanol injected into one posterior trochanteric (saddlebag) area with the other side untreated, sonography and Lipometer follow-up to week 20

    No significant reduction of subcutaneous fat was achieved on the treated side compared with the untreated side. Transient inflammatory reactions occurred in all patients.

  25. 25Clinique humaine2007

    Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects.

    Yagima Odo ME, et al. · Dermatol Surg · randomised placebo-controlled study, thirty volunteers, subcutaneous abdominal injections of sodium deoxycholate at two concentrations or placebo, clinical, blood and ultrasound follow-up for 3 months and histology at 3 and 6 months

    Both concentrations caused an inflammatory reaction with dose-dependent adipocyte lysis and fat necrosis; participants reported heat, erythema, swelling and intense pain, ultrasound showed nodules at injection sites, and fibrosis was seen at 6 months. Placebo caused no histologic changes, and no systemic effects were detected.

    Résultat de sécurité signalé. Intense injection pain, nodules and later fibrosis followed sodium deoxycholate injection.

  26. 26Animal in vivo2025

    Peripheral Nerve Injury After Deoxycholic Acid (ATX-101) Injection in an Experimental Rat Model

    Chi D, Pinni S, Maloy S, Llaneras N, Hunter DA, et al. · Aesthetic Surgery Journal · rat sciatic nerve model comparing intrafascicular ATX-101 injection with saline control

    Intrafascicular ATX-101 injection produced 75% (SD 15%) nerve fibre damage compared with 7% in saline controls. Histology indicated a demyelinating pattern of injury with Wallerian degeneration evident at two weeks.

  27. 27In vitro2026

    Extracellular phosphatidylcholine functions as a noncanonical TLR4 activator to drive adipocyte lipolysis and apoptosis

    Lim DS, Bae KL, Pyo MK, Ko JH, Choi JK, et al. · Frontiers in Pharmacology · 3T3-L1 adipocytes exposed to phosphatidylcholine at 0-25 mg/mL

    Phosphatidylcholine reduced adipocyte viability in a concentration-dependent manner and induced lipolysis and apoptosis. TLR4 inhibition attenuated these effects, implicating a TLR4-NF-kappaB-TNF-alpha signalling axis.

  28. 28In vitro2004

    Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution

    Rotunda AM, Suzuki H, Moy RL, Kolodney MS · Dermatologic Surgery · in vitro cell lysis assays and porcine/human tissue exposure to phosphatidylcholine-deoxycholate formulation components

    Cell lysis produced by the injectable phosphatidylcholine formulation was attributed principally to its sodium deoxycholate excipient, which behaved comparably to standard laboratory detergents. The authors described the effect as non-specific membrane disruption rather than a phosphatidylcholine-mediated metabolic action.

  29. 29Revue2026

    Injection lipolysis in aesthetic medicine: mechanisms, clinical safety, and clinical applications

    Ao Y, Zhou Y · Frontiers in Medicine · narrative review of injection lipolysis mechanisms, safety and indications

    The review described deoxycholic acid as preferentially disrupting adipocytes with relative tissue selectivity and identified the submental fat pad as the best-documented indication. Skin necrosis and nerve injury were reported as consequences of improper injection technique.

  30. 30Revue2024

    Lipolytic agents for submental fat reduction: Review

    Park SY, Kim SB, Wan J, Felice F, Yi KH · Skin Research and Technology · narrative review of lipolytic agents used in the submental region

    The review compared aminophylline, phosphatidylcholine and deoxycholic acid, noting that the mechanisms of several agents remain incompletely characterised. The authors emphasised submental anatomy as central to avoiding neurovascular injury.

  31. 31Revue2022

    Injection lipolysis with phosphatidylcholine and sodium deoxycholate-Is it really worth the risk?

    Fratczak A, Polak K, Szczepanek M, Waliczek M, Bergler-Czop B · Dermatologic Therapy · commentary/letter reviewing safety of compounded phosphatidylcholine-sodium deoxycholate lipolysis

    The authors questioned the risk-benefit balance of phosphatidylcholine and sodium deoxycholate injection lipolysis. Concerns raised centred on the adverse-event burden relative to the strength of supporting efficacy data.

  32. 32Rapport de cas2026

    Dermal Necrosis and Chronic Abscess Formation Following Fat Dissolving Injections Administered by a Non-Medical Practitioner: A Case Report

    Naem A, et al. · · preprint, not peer reviewed; single case, 33-year-old woman given injections of a lipolytic product purported to be 'Lemon Bottle' into the abdomen and thighs by a non-medical practitioner

    Painful subcutaneous nodules progressed over several months to chronic abdominal wall abscesses with sterile purulent material and necrotic thigh lesions, and several antibiotic courses did not help. Histopathology showed dermal necrosis, ulceration, chronic inflammation and dense scar tissue consistent with chemical injury, and symptoms resolved after incision and drainage and surgical excision.

    Résultat de sécurité signalé. Dermal necrosis and chronic sterile abscesses followed injections of a product purported to be Lemon Bottle.

  33. 33Rapport de cas2026

    Possible ARDS Following Cosmetic Lipolysis: A Case Report Urging Caution in Aesthetic Medicine.

    Phan TT, et al. · Am J Case Rep · single case, previously healthy 41-year-old woman given multiple abdominal, shoulder and thigh fat-dissolving (lipolysis) injections at an unlicensed cosmetic facility; product not identified

    About 30 minutes after the injections she developed progressive dyspnoea and bilateral chest pain, with diffuse bilateral infiltrates progressing to hypoxaemic respiratory failure consistent with ARDS. Pulmonary embolism and macroscopic fat embolism were excluded, and she improved within days with high-flow oxygen, corticosteroids and antibiotics.

    Résultat de sécurité signalé. Acute respiratory distress syndrome followed cosmetic fat-dissolving injections.

  34. 34Rapport de cas2022

    Hemolysis after subcutaneous deoxycholic acid overdose.

    Sharpe A, et al. · Am J Emerg Med · single case, patient self-injecting deoxycholic acid with benzyl alcohol for cosmetic purposes without medical supervision, at a 10-fold overdose relative to approved dosing

    Haemolysis was reported after the unsupervised subcutaneous overdose of deoxycholic acid. Further clinical details are not given in the abstract.

    Résultat de sécurité signalé. Haemolysis after unsupervised subcutaneous deoxycholic acid overdose.

  35. 35Rapport de cas2022

    Painful Purulent Nodules Caused by Mycobacterium at Site of Lipodissolve Injections.

    Kaur H, et al. · Am J Dermatopathol · single case, 53-year-old woman given Lipodissolve (phosphatidylcholine in deoxycholate) injections to both upper arms; 3 similar infections were traced to the same office

    Painful nodules appeared at each injection site one week later and did not respond to trimethoprim/sulfamethoxazole; biopsy showed suppurative granulomatous inflammation and culture grew Mycobacterium abscessus. Symptoms resolved with intravenous amikacin, azithromycin and bedaquiline.

    Résultat de sécurité signalé. Mycobacterium abscessus infection at Lipodissolve injection sites, part of a cluster from one office.

  36. 36Rapport de cas2022

    Chronic Infection and Nodule Formation following Deoxycholate Injection.

    Shahid S, Al-Hassani F · Arch Plast Surg · single case, patient given a deoxycholate fat-dissolving injection advertised as Aqualyx by someone who was not a trained health professional, injected too superficially

    Severe pain, localised skin necrosis and palpable collections developed, and numerous painful nodules later ruptured onto the skin as purulent and bleeding lesions. Ultrasound showed a superficial hypoechoic lesion without deeper spread.

    Résultat de sécurité signalé. Skin necrosis and chronic painful nodules after a deoxycholate fat-dissolving injection given by an untrained practitioner.

  37. 37Rapport de cas2020

    Inadvertent intra-arterial injection of deoxycholic acid: A case report and proposed protocol for treatment.

    Lindgren AL, Welsh KM · J Cosmet Dermatol · single case, 42-year-old woman given deoxycholic acid (ATX-101) for submental fullness, complicated by inadvertent intra-arterial injection

    Management adapted from published protocols for inadvertent intra-arterial injection of sclerosing solutions and dermal fillers led to a good outcome. The authors noted that necrosis can follow superficial or intra-arterial injection and proposed a treatment protocol.

    Résultat de sécurité signalé. Inadvertent intra-arterial injection of deoxycholic acid during submental treatment.

  38. 38Rapport de cas2013

    Woman with hemorrhagic spots on her abdomen.

    Kyong YY, Choi KH · Clin Toxicol (Phila) · single case, woman after a Lipodissolve (phosphatidylcholine and deoxycholate mixture) injection

    Agitation and metabolic acidosis were reported after lipodissolve injection, and the title describes haemorrhagic spots on the abdomen. Further clinical details are not given in the abstract.

    Résultat de sécurité signalé. Agitation and metabolic acidosis followed a phosphatidylcholine-deoxycholate (Lipodissolve) injection.

  39. 39Rapport de cas2011

    Acute renal failure and liver dysfunction after subcutaneous injection of 3-sn-phosphatidylcholine (Lipostabil®)-case report.

    Rey JW, et al. · Z Gastroenterol · single case, 28-year-old woman given a large subcutaneous injection of phosphatidylcholine (Lipostabil) into both gluteal regions for off-label fat reduction

    Severe nausea and vomiting began three hours after injection, liver enzymes rose sharply with early liver dysfunction within 24 hours, and renal function deteriorated two days later, requiring temporary haemodialysis. Liver function improved after three days of treatment and renal function fully recovered after two weeks.

    Résultat de sécurité signalé. Acute liver dysfunction and renal failure requiring haemodialysis followed subcutaneous phosphatidylcholine (Lipostabil) injection.

Limites

Ce que ces preuves n'établissent pas.

No peer-reviewed clinical trial, case report or mechanistic study of the branded 'Lemon Bottle' formulation was identified in Europe PMC or PubMed; the only human report found is a 2026 preprint, not peer reviewed, describing dermal necrosis and chronic abscesses after injections of a product purported to be Lemon Bottle, so its composition, potency and safety profile are not independently characterised in the scientific literature. Controlled evidence for compounded phosphatidylcholine-deoxycholate products, for non-submental body sites and for long-term outcomes beyond three years remains limited, and comparative trials against surgical or device-based fat reduction are largely absent.

Questions courantes sur la recherche.

What is Lemon Bottle?

Lemon Bottle is a ready-mixed 10 ml research solution in the lipolytic-solution category, marketed as combining riboflavin, bromelain, and lecithin-derived phosphatidylcholine. It is supplied strictly for laboratory research into the constituent compounds' biochemistry.

What does the research literature say about phosphatidylcholine solutions?

The cited review traces the history of phosphatidylcholine injection research, and a randomised controlled study examined phosphatidylcholine–deoxycholate preparations at the adipocyte level. Notably, that literature attributes much of the observed in-vitro activity to the deoxycholate detergent co-solvent rather than to phosphatidylcholine itself.

Has Lemon Bottle itself been studied in controlled trials?

No. The specific formulation has not been the subject of published controlled trials, and its composition is not standardised in the peer-reviewed literature. Only constituent-level research is cited on this page, and no conclusions about the mixture should be drawn from it.

What roles do riboflavin and bromelain play in the cited research?

Riboflavin is the precursor of the flavin coenzymes FAD and FMN, which participate in mitochondrial oxidation reactions. Bromelain is a pineapple-derived proteolytic enzyme complex characterised for fibrinolytic and anti-edematous enzymology. Both literatures describe general biochemistry, not effects of this product.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.